Comparative Pharmacology
Head-to-head clinical analysis: ALSUMA versus AMERGE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALSUMA versus AMERGE.
ALSUMA vs AMERGE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25, a protein required for synaptic vesicle fusion.
Selective serotonin 5-HT1B/1D receptor agonist; binds to 5-HT1B and 5-HT1D receptors on cranial blood vessels and trigeminal nerve endings, causing vasoconstriction and inhibition of pro-inflammatory neuropeptide release.
0.5 mg intramuscularly every 4 weeks
2.5 mg orally at onset of migraine; may repeat after 4 hours if needed, maximum 5 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life: 9-11 hours; clinically, steady-state achieved in ~2 days
Terminal elimination half-life is approximately 26 hours (range 13-40 hours). This long half-life allows for once-daily dosing for prophylaxis, but may prolong the duration of adverse effects.
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other
Renal excretion accounts for approximately 50% of the dose, with about 40% as unchanged drug and 10% as metabolites. Fecal excretion accounts for 30% of the dose. The remainder is unknown.
Category C
Category C
Triptan Antimigraine
Triptan Antimigraine